Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.
about
PET and MR imaging: the odd couple or a match made in heaven?Photoacoustic Imaging of Cancer Treatment Response: Early Detection of Therapeutic Effect from Thermosensitive LiposomesPediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessmentPrognostic Significance of Volume-based Metabolic Parameters by (18)F-FDG PET/CT in Gallbladder Carcinoma.2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.Prognostication and Risk-Adapted Therapy of Hodgkin's Lymphoma Using Positron Emission Tomography.Tailored strategies for radiation therapy in classical Hodgkin's lymphoma.Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.Role of positron emission tomography-computed tomography in staging and early chemotherapy response evaluation in children with neuroblastomaFDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.Simultaneous [18F]FDG-PET/MRI: Correlation of Apparent Diffusion Coefficient (ADC) and Standardized Uptake Value (SUV) in Primary and Recurrent Cervical Cancer.Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology GroupThe role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphomaDetermination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients.Pulmonary inflammatory myofibroblastic tumour after Hodgkin's lymphoma.Clinical applications of PET and PET/CT in pediatric malignancies.Whole-body diffusion-weighted imaging for staging malignant lymphoma in children.The role of PET in Hodgkin's lymphoma and its impact on radiation oncology.Pediatric oncology and the future of oncological imaging.FDG PET/CT in children and adolescents with lymphoma.The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.Outcome of Hodgkin Lymphoma Patients With a Posttreatment 18F-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography (FDG-PET)-Negative Residual Mass: Systematic Review and Meta-analysis.Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria.Imaging of Tumor Metabolism Using Positron Emission Tomography (PET).How PET/MR Can Add Value For Children With Cancer.Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy?Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: an analysis of 21 734 cases.qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.The Gordian knot of interim 18-fluorodeoxyglucose positron emission tomography for Hodgkin lymphoma: a meta-analysis and commentary on published studies.Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy.Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee.SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: is there a benefit for PPV in early response assessment by FDG-PET?Ultra-early response assessment in lymphoma treatment: [18F]FDG PET/MR captures changes in glucose metabolism and cell density within the first 72 hours of treatment.Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma.[Simultaneous whole-body PET-MRI in pediatric oncology : More than just reducing radiation?].Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.18F-FDG PET/CT compared to conventional imaging modalities in pediatric primary bone tumors.Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease.
P2860
Q26851721-B1857637-78DA-49F0-87EC-338D95814E2FQ28553001-D25CA623-0780-4748-8BB1-3EB3C51D7360Q30363610-6E337CB6-58F9-49E2-B17C-39F9D1AE86E2Q33704511-38652871-E229-4A33-8D15-787F307F1967Q34404416-FBCF23B2-B107-44E0-9C2D-99CEE28E43DDQ34495333-BB708822-521C-4074-9E08-23530FB41EA0Q34610653-732D17D3-981C-4E23-9F5A-78AC5010B694Q34878992-D34B38D5-27A9-4BF2-A48D-537440A0D77BQ35030243-7F248C4D-E445-43DF-BA4C-878549FB05FAQ35237507-9C7C86CD-2739-499A-90FA-BD42FC6D7FB0Q35836090-23054432-CB09-46BB-B926-11581B1AB3D5Q36025958-07B20A7A-BC81-4ACC-9701-C4CD389DF4D6Q37058257-2466BAF7-3580-4E80-8295-D59E169A079EQ37261280-1F02FC82-6F4D-402C-B314-E99AEA638924Q37369885-E2AB0783-2A7C-400C-9502-5B6350DA5C57Q37550064-3A6260B2-1411-47AE-A40D-A79F0A329669Q37752394-8E8F744F-0314-48C1-87E5-0A6648952430Q37777048-349A1529-7308-4CFE-99AA-FA66301C3629Q37788240-5FB6E5BE-F13D-41B0-AC4D-8146D8BD765CQ37869417-A41D8771-6A80-4384-B106-BB4029259A48Q38092706-190B47A8-F0A2-4FC4-BC93-8E840D35B8E6Q38096322-C36C4C62-19C1-4BEB-B5C2-289EEFEC9D63Q38631480-CE003CF5-7E48-4DA6-82CE-87910FFBB974Q38663136-287AFE9E-8AFE-42E4-B098-66A7357CB2F5Q38936273-C3AC119A-DD96-42DA-A4DF-8AADE18F04E4Q39427334-8BC0879C-E3A7-482C-AD14-BCA96F4773D8Q39518368-79C7027B-1A9C-4D7F-88A3-798896B6606DQ43526086-161B7BB3-A67F-45FA-9506-2AB6F8701AFBQ44307668-6D507FD8-F5B4-47D4-90A7-67D60CC3B555Q45428337-05C9553B-EF37-4DBB-A32F-E1EF7286863EQ48190235-FF56F0FE-3539-40FF-87F0-E986B9C93EB7Q48194998-FF323A13-7B1E-426C-B186-BFAD5F5B952EQ48371908-58217D3C-59C4-4D0B-A589-8488F1602921Q51373515-0D48EF03-29AC-4E79-875C-B2FDC640E666Q52685638-7637CFB1-7BE7-499C-BA50-F1CB92770FC5Q52803394-CB0591A8-BC69-4BEE-90E5-78C97C3B99EDQ52982322-8A4331A4-98B2-4C0D-AD62-6EAC84EB0BD5Q52986952-C1E599FC-4319-4499-83BC-159D21F1DBEFQ53187964-46D28759-BF9B-4712-91EB-D0C23430DB46Q53225891-3EABF2DD-FFEC-4192-9833-ED4AD84ED621
P2860
Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Early and late therapy respons ...... prospective multicenter trial.
@en
Early and late therapy respons ...... prospective multicenter trial.
@nl
type
label
Early and late therapy respons ...... prospective multicenter trial.
@en
Early and late therapy respons ...... prospective multicenter trial.
@nl
prefLabel
Early and late therapy respons ...... prospective multicenter trial.
@en
Early and late therapy respons ...... prospective multicenter trial.
@nl
P2093
P356
P1476
Early and late therapy respons ...... prospective multicenter trial
@en
P2093
Brigitte Stöver
Carsten Kobe
Christian Furth
Daniel Misch
Günter Henze
Holger Amthauer
Hubertus Hautzel
Ingo G Steffen
Patrick Hundsdoerfer
P304
P356
10.1200/JCO.2008.19.7814
P407
P577
2009-08-10T00:00:00Z